Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates. For Sana, that means halting work on a…
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech works to understand…
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren…
Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current hormone therapies for prostate cancer and benign prostatic hyperplasia (BPH). Teverelix is a…
The FDA has released the second batch of recipients for the new “national priority voucher” program, with executives for two of the beneficiaries appearing in the Oval Office with President…
More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of…
Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue Therapeutics’ subsidiary Baergic Bio, in a deal potentially worth more than $83 million.…
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development. New Jersey-based UroGen forked…
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere…
Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month. Lilly showed…